Table 2 Clinical symptoms, CT findings, laboratory test results and microbial detection results of patients at the time of IP diagnosis
Patient ID | Symptoms | CT findings | Neutrophil count (*109/L) | CRP (mg/L) | BDG and GM assays | Routine laboratory staining and cultures | mNGS outcome | Course of prednisone ≥ 20 mg/d | Antimicrobial therapy | Recovery time |
|---|---|---|---|---|---|---|---|---|---|---|
P1 | Fever Dyspnea | Diffuse GGO | 10 | 98 | Negative | Negative | Pneumocystis jirovecii | 5 days | TMP-SMX, moxifloxacin | 5 days |
P2 | Fever Dyspnea | Diffuse GGO | 8.3 | 39.3 | Negative | Negative | Campylobacter mucosa Pneumocystis jirovecii | No glucocorticoids were used | TMP-SMX, piperacillin-tazobactam, imipenem/cilastatin | 5 days |
P3 | Fever | Diffuse GGO | 0.6 | 83 | Negative | Negative | Pseudostreptococcus pneumoniae EBV Pneumocystis jirovecii | No glucocorticoids were used | TMP-SMX, piperacillin-tazobactam | 20 days |
P4 | Fever Dyspnea | Diffuse patchy exudation | 13.3 | 62 | Negative | Klebsiella pneumoniae | EBV Candida albicans | 3 months | Caspofungin, linezolid, imipenem/cilastatin | 3.5 months |
P5 | Fever Dyspnea | Diffuse GGO | 2.2 | 10.6 | Positive BDG assay (361.9 pg/mL) | Negative | CMV Pneumocystis jirovecii | 3 months | TMP-SMX, caspofungin, moxifloxacin, voriconazole | 1 year |
P6 | Fever Dyspnea | Diffuse patchy exudation | 0.6 | 61 | Negative | Negative | CMV Pneumocystis jirovecii | 14 days | TMP-SMX, voriconazole, moxifloxacin, teicoplanin | 2 months |
P7 | Fever Dyspnea | Diffuse GGO | 2.2 | 14.1 | Negative | Negative | Pneumocystis jirovecii | 1.5 months | TMP-SMX, caspofungin, voriconazole | 5 months |
P8 | Fever Dyspnea | Diffuse GGO | 1.1 | 277 | Positive BDG assay (275.34 pg/mL) | Negative | Pneumocystis jirovecii | 1 months | TMP-SMX, caspofungin, piperacillin-tazobactam | 1.5 months |
P9 | Fever Cough Dyspnea | Diffuse GGO | 2.9 | 92.4 | Negative | Negative | EBV Pneumocystis jirovecii | 3 months | TMP-SMX, caspofungin, piperacillin-tazobactam | 4.3 months |
P10 | No symptom | Diffuse GGO | 2.4 | 25.2 | No data | Negative | Negative | 5 days | TMP-SMX | 9 days |
P11 | Fever Dyspnea | Diffuse GGO | 20.8 | 35.8 | No data | Negative | Acinetobacter baumannii Pneumocystis jirovecii | 1 month | TMP-SMX, caspofungin, piperacillin-tazobactam | 15 days |
P12 | Fever Cough Sputum | Diffuse GGO | 3 | 34 | Positive BDG assay (153.72 pg/mL) | Staphylococcus aureus | Pseudomonas aeruginosa Pneumocystis jirovecii | No glucocorticoids were used | TMP-SMX, piperacillin-tazobactam | 30 days |
P13 | Fever | Diffuse GGO | 10 | 11.8 | Negative | Negative | Escherichia coli Pneumocystis jirovecii CMV | No glucocorticoids were used | TMP-SMX, caspofungin, piperacillin-tazobactam, ganciclovir | 2 months |
P14 | Fever | Diffuse GGO | 8.3 | 115 | Positive BDG assay (129.14 pg/mL) | Negative | Pneumocystis jirovecii | No glucocorticoids were used | TMP-SMX, piperacillin-tazobactam | 15 days |
P15 | Fever Dyspnea | Diffuse GGO | 0.6 | 60.6 | Negative | Negative | CMV | 15 days | TMP-SMX, piperacillin-tazobactam, ganciclovir | 1 month |